Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexagen is a topical antimicrobial ointment and wound dressing developed by Turn Therapeutics, primarily indicated for the management of acute and chronic wounds, burns, eczema, and as a skin and nasal antiseptic. The formulation uses a proprietary nanodroplet suspension technology in a petrolatum base with active antimicrobial preservatives including polyhexamethylene biguanide (PHMB) and benzalkonium chloride (BZK). It is non-cytotoxic, non-sensitizing, non-irritating, and designed to maintain moisture at the wound or skin surface to promote healing. Documented activity includes protection against MRSA, Staphylococcus aureus, Candida auris/albicans, human coronavirus, Pseudomonas species; it exhibits antiviral, antibacterial, antifungal properties. The product has FDA clearance for use in managing eczema symptoms and is being investigated for additional indications such as onychomycosis (toenail fungus)[1][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hexagen.